Tempest Reports First Quarter 2026 Financial Results and Provides Business Update
Tempest Presents Clinical Update at ISCT 2026 Annual Meeting
Tempest to Advance Dual-Targeting CAR-T Platform with Clinical Update at ISCT 2026 Annual Meeting
Tempest Announces Key Manufacturing Milestone for TPST-2003 Dual-Targeting CD19/BCMA CAR-T
Tempest Appoints Andrew Fang, Ph.D., as Head of Business Development to Advance Strategic Partnerships and Global Licensing Efforts
New Strong Buy Stocks for April 10th
Tempest Reports Year End 2025 Financial Results and Provides Business Update
Matthew Angel Purchases 231,482 Shares of Tempest Therapeutics (NASDAQ:TPST) Stock
Tempest Therapeutics (TPST) Projected to Post Quarterly Earnings on Wednesday
Tempest Therapeutics Announces Up To $6 Million Private Placement
Head-To-Head Review: Shuttle Pharmaceuticals (NASDAQ:SHPH) versus Tempest Therapeutics (NASDAQ:TPST)
Tempest Announces Partnership for TPST-2003 in Preparation for Planned U.S. Registrational Study in 2026
Tempest Announces Interim Results from Ongoing REDEEM-1 Trial of TPST-2003, Preparing for Potential U.S. Registrational Study in 2026
Tempest Lays Out Strategic Plan to Advance Recently Acquired Dual-Targeting CAR-T Assets
Tempest Announces Closing of Strategic Acquisition of Dual-Targeting CAR-T Assets
Tempest Therapeutics (NASDAQ:TPST) Shares Scheduled to Split on Friday, January 30th
Tempest Announces Record Date for Anticipated Dividend Distribution of Warrants to Stockholders
Tempest Announces Closing of Up To $8.35 Million Registered Direct Offering of Common Stock and Concurrent Private Placement of Warrants Priced At-the-Market Under Nasdaq Rules
Tempest Announces Up To $8.35 Million Registered Direct Offering of Common Stock and Concurrent Private Placement of Warrants Priced At-the-Market Under Nasdaq Rules
Tempest Announces Strategic Acquisition of New Dual-CAR T Programs from Factor with Simultaneous Runway Extension Projected to Mid 2027
Tempest Reports Third Quarter 2025 Financial Results and Provides Business Update
Tempest Reports Second Quarter 2025 Financial Results and Provides Business Update
Tempest Receives Clearance to Proceed with Pivotal Trial of Amezalpat Combination Therapy for First-Line HCC in China
Tempest Announces $4.6 Million Registered Direct Offering of Common Stock
TPST Stock Up on EMA's Orphan Drug Tag for Liver Cancer Therapy
Tempest Receives Orphan Drug Designation from the European Medicines Agency for Amezalpat for the Treatment of Patients with HCC
Tempest Reports First Quarter 2025 Financial Results and Provides Business Update
Tempest Presents New Amezalpat MOA Data Reinforcing Its Potential as Novel Cancer Treatment at the 2025 AACR Annual Meeting
Tempest Receives Orphan Drug Designation from the FDA for TPST-1495 to Treat Patients with FAP
TPST to Evaluate Strategic Options for Pipeline Studies, Stock Up
Tempest Announces Plan to Explore Strategic Alternatives to Advance Promising Pipeline of Clinical Oncology Assets and Maximize Stockholder Value
Tempest Reports Year End 2024 Financial Results and Provides Business Update
Tempest Announces Amezalpat Poster Presentation at the 2025 American Association for Cancer Research (AACR) Annual Meeting
FDA Study May Proceed Notice Received for Phase 2 Trial of TPST-1495 for the Treatment of Familial Adenomatous Polyposis (FAP)
Tempest Granted Fast Track Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma
Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Tempest Receives Orphan Drug Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma (HCC)
Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Tempest to Participate in the Piper Sandler 36th Annual Healthcare Conference
Tempest Reports Third Quarter 2024 Financial Results and Provides Business Update
Why Is Cancer Focused Tempest Therapeutics Stock Trading Higher On Thursday?
Tempest Announces Agreement with Roche to Support Advancement of Amezalpat Combination Therapy into First-Line Hepatocellular Carcinoma Pivotal Trial
Tempest Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Tempest to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Tempest Announces Successful End-of-Phase 2 Meeting with FDA for Amezalpat (TPST-1120) to Treat First-Line Hepatocellular Carcinoma
Tempest Reports Second Quarter 2024 Financial Results and Provides Business Update
What's Going On With Cancer-Focused Tempest Therapeutics Stock On Thursday?
Why Is Tempest Therapeutics (TPST) Stock Up 45% Today?
Tempest to Report New Data from Global Randomized Combination Study of Amezalpat (TPST-1120) in First-Line Hepatocellular Carcinoma